|
1
|
Combination echinocandin-polyene treatment of murine mucormycosis.
|
Antimicrob Agents Chemother
|
2008
|
1.43
|
|
2
|
The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis.
|
Mol Microbiol
|
2010
|
1.27
|
|
3
|
Posaconazole mono- or combination therapy for treatment of murine zygomycosis.
|
Antimicrob Agents Chemother
|
2008
|
1.15
|
|
4
|
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
|
J Antimicrob Chemother
|
2009
|
1.08
|
|
5
|
CotH3 mediates fungal invasion of host cells during mucormycosis.
|
J Clin Invest
|
2013
|
1.04
|
|
6
|
Isavuconazole therapy protects immunosuppressed mice from mucormycosis.
|
Antimicrob Agents Chemother
|
2014
|
1.01
|
|
7
|
Comparison of lipid amphotericin B preparations in treating murine zygomycosis.
|
Antimicrob Agents Chemother
|
2008
|
0.98
|
|
8
|
Diabetic murine models for Acinetobacter baumannii infection.
|
J Antimicrob Chemother
|
2012
|
0.98
|
|
9
|
Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis.
|
J Infect Dis
|
2008
|
0.95
|
|
10
|
NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response.
|
Vaccine
|
2013
|
0.94
|
|
11
|
Combination therapy of murine mucormycosis or aspergillosis with iron chelation, polyenes, and echinocandins.
|
Antimicrob Agents Chemother
|
2011
|
0.93
|
|
12
|
Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis.
|
Antimicrob Agents Chemother
|
2013
|
0.91
|
|
13
|
Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis.
|
J Clin Invest
|
2016
|
0.75
|